ライフサイエンスコーパス: trough concentration

1 rve at steady-state and minimum steady-state trough concentration.

2 the first three cycles to evaluate valspodar trough concentration.

3 n variants in the AA group towards the first trough concentrations.

4 L loading dose and a reduction in TAC target trough concentrations.

5 e pulmonary epithelial lining fluid peak and trough concentrations.

6 cin and related them to high- and low-target trough concentrations.

7 were found to be associated with tacrolimus trough concentrations.

8 observed only in the presence of antibiotic trough concentrations.

9 ic outcomes it is recommended to monitor IFX trough concentrations.

10 erse event-related dose reductions at higher trough concentrations.

11 ts achieving predefined reduced cyclosporine trough concentrations.

12 Ganciclovir trough concentrations 0.60 ug/mL have been suggested for

13 nterally every 24 hours achieved ganciclovir trough concentrations 0.60 ug/mL in most patients on CVV

14 nterally every 24 hours achieves ganciclovir trough concentrations 0.60 ug/mL in patients on CVVHD.

15 to 3.16 ug/mL, and 80% of participants have trough concentrations 0.60 ug/mL.

16 ugh concentration from first to second dose (trough concentration = 0.822 and 1.23 ng/mL for weeks 1

17 for weeks 1 and 2, respectively, with 24 mg; trough concentration = 0.993 and 1.47 ng/mL for weeks 1

18 morphism rs2244613 was associated with lower trough concentrations (15% decrease per allele; 95% conf

19 detectable HCV RNA (29% vs 25%) and mean RBV trough concentration (2.48 vs 2.14 mug/mL) were comparab

20 he primary pharmacokinetic parameter was the trough concentration 24 h after observed dolutegravir in

21 rs plus postbaseline model-predicted CAB/RPV trough concentrations (4 and 44 weeks postinjection).

22 g intervals and observed wide variability in trough concentrations (6.7-fold for meropenem, 3.8-fold

23 0 mug/mL vs. 53.0 +/- 12.3 mug/mL) and lower trough concentrations (7.2 +/- 5.2 mug/mL vs. 12.3 +/- 5

24 emission than reactive monitoring (measuring trough concentration after loss of response).

25 tive monitoring (physicians were informed of trough concentrations after loss of response, n = 40).

26 dolutegravir that achieves the targeted 24-h trough concentration and 24-h area under the curve for i

27 the association between discharge tacrolimus trough concentration and the incidence of biopsy-proven

28 sulted in 81% inhibition of FXIa activity at trough concentrations and 90% inhibition at peak concent

29 undexian 50 mg resulted in 92% inhibition at trough concentrations and 94% inhibition at peak concent

30 ound that proactive monitoring of adalimumab trough concentrations and adjustment of doses and interv

31 Proactive monitoring of drug trough concentrations and antibodies against drugs might

32 higher doses of tacrolimus to achieve target trough concentrations and are more likely to experience

33 se interferon alfa-2b and ribavirin peak and trough concentrations and area-under-the-curve were simi

34 nd whole blood containing peak, midpoint, or trough concentrations and incubated for up to 120 hours

35 ealed an independent association between VRC trough concentrations and probability of response or neu

36 We evaluated mean TAC C0 (tacrolimus trough concentration) and TAC time in therapeutic range

37 e polymorphism rs2244613 was associated with trough concentrations, and the ABCB1 single-nucleotide p

38 of intrapatient variability for cyclosporine trough concentrations as determined by %CV (P<0.05).

39 At a given dose, peak and trough concentrations, as well as serum neutralization t

40 ons for all products were several-fold below trough concentrations associated with oral tenofovir dis

41 The mean+/-SD tacrolimus trough concentration at discharge (median postoperative

42 median (interquartile range) daily dose and trough concentration at time of nephrotoxicity were 400

43 MK-8527-triphosphate trough concentrations at 0.1 mg/kg resulted in a mean in

44 using doses selected to maintain whole blood trough concentrations at therapeutic values between 40 a

45 us was calculated as the area under curve of trough concentrations (AUCtc).

46 This study illustrates that trough concentration-based AUC24h estimation is a feasib

47 eek after transplantation nor time to target trough concentration between patients later experiencing

48 Cyclosporine doses were adjusted to achieve trough concentrations between 100 and 300 ng/mL.

49 at 2 mg once daily and adjusted to maintain trough concentrations between 3-12 ng/mL through to day

50 g/day, whichever dose was lower, to maintain trough concentrations between 5 and 15 ng/mL.

51 oncentration-time curves, and >/=36% for the trough concentration (C(0)).

52 d significantly enhanced plasma exposure and trough concentration (C(min) at 24 h) of 1 in rats while

53 ping patients into quartiles according to IM trough concentration (C(min)).

54 ion (C(max)), apparent clearance (CL/F), and trough concentration (C(trough)) in participants who com

55 the curve (AUC(0-6 weeks)) and steady-state trough concentration (C(trough)) of pembrolizumab.

56 Primary outcomes were trough concentration (C(trough)), maximum concentration

57 time to reach peak plasma concentration, and trough concentration (C(trough)).

58 endpoints were overall response and maximum trough concentration (C(trough); cycle 3, day 1 pre-dose

59 -inferiority of the cycle 7 pertuzumab serum trough concentration (C(trough); ie, cycle 8 predose per

60 s, saquinavir area under the curve (AUC) and trough concentrations (C(min)), and virologic response.

61 Target dolutegravir trough concentrations (C(trough)) were based on referenc

62 armacokinetic noninferiority end points were trough concentrations (C(trough); on cycle-2-day-1 or cy

63 ms with SRL dose-adjusted, weight-normalized trough concentrations (C/D) at 7 days, and at 1, 3, 6, a

64 (ratios of the maximum concentration and the trough concentration) C(max)/C(trough) window.

65 nce, pretransplant laboratory values and SRL trough concentrations (C0) were correlated with the occu

66 study, and correlated with plasma ritonavir trough concentrations (C24).

67 cted a pharmacokinetic study to evaluate EFV trough concentrations (Cmin) and human immunodeficiency

68 e exposures (area under the curve [AUC]) and trough concentrations (Cmin) for monthly and bimonthly a

69 Efavirenz trough concentrations (Cmin) were predicted using popula

70 However, whole blood trough concentrations commonly utilized in TDM are not s

71 (TAC) formulation and has a good exposure to trough concentration correlation.

72 Only 1 patient showed a trough concentration (Ctrough) below the suggested targe

73 n SC dose that would yield a rituximab serum trough concentration (Ctrough) in the same range as that

74 BV/PTV/r + DSV + darunavir (DRV) lowered DRV trough concentration (Ctrough) levels.

75 The individual target trough concentration (Ctrough) was defined as 0.32 mg/L.

76 both area under the curve (AUC0-28 days) and trough concentration (Ctrough, 28th day) of LA cabotegra

77 characterize the variability of CAB and RPV trough concentrations (Ctrough) and to identify the pred

78 nt was the ratio of observed rituximab serum trough concentrations (Ctrough) between groups at cycle

79 iated with toxicity, while lowering elevated trough concentrations did not restore baseline risk.

80 ong randomized trials the mean of tacrolimus trough concentration during the first month was positive

81 one-third of patients, it was observed that trough concentrations exceeded the therapeutic window.

82 One-third of patients had an adalimumab trough concentration exceeding 7 mg/L.

83 Trough concentrations failed to meet optimal higher limi

84 domized trials directly comparing tacrolimus trough concentrations (five trials for acute rejection [

85 The median (IQR) trough concentration for meropenem was 12.1 mg/L (7.9-18

86 ) and higher eTRCL was associated with lower trough concentrations for all antibiotics (P < .05).

87 5 days and approximately 50% accumulation of trough concentration from first to second dose (trough c

88 Overall, participants with a mean infliximab trough concentration greater than 8ug/ml were more likel

89 Maintenance-phase infliximab trough concentrations greater than 8 ug/ml, which is hig

90 1.26-4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55-4.47; P < .0

91 A maximum linezolid trough concentration >2 mg/L was detected in 52 patients

92 .01) for SMT after the first detection of a trough concentration >2 mg/L.

93 leukopenia correlated significantly with SRL trough concentrations > or =16 ng/ml (P=0.001 and 0.0001

94 Linezolid trough concentrations >2 mg/L are strongly associated wi

95 The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivaria

96 d treatment is warranted in any patient with trough concentrations >2 mg/L.

97 +/- 0.3 g/day and the individual median MPA trough concentration in the time period of anticipated c

98 The median tacrolimus trough concentration in week 1 posttransplant was partic

99 Similarly, median (IQR) time-averaged trough concentrations in breast milk were 3.3 ng/mL (2.3

100 ere is significant variability in antibiotic trough concentrations in critically ill patients receivi

101 cfDNA, anellovirus abundance, and tacrolimus trough concentrations in serum over the study period and

102 creased proportionally up to 120 mg/day with trough concentrations in the in-vitro active range from

103 of dosage to maintain whole blood tacrolimus trough concentrations in the usual therapeutic range can

104 Trough concentrations increased less than proportionally

105 28.6%) of the 119 patients with a tacrolimus trough concentration less than 8 ng/mL and 19 (19.6%) of

106 on predisposed to BPAR, discharge tacrolimus trough concentration less than 8 ng/mL was associated wi

107 el-reactive antibody, a discharge tacrolimus trough concentration less than 8 ng/mL was significantly

108 en occurred among patients who displayed SRL trough concentrations < or =9 ng/ml.

109 [n = 712]) showed that "reduced tacrolimus" trough concentrations (<10 ng/mL) within the first month

110 Inclusion of initial model-predicted CAB/RPV trough concentrations (<=first quartile) did not improve

111 emic exposure of tacrolimus, despite similar trough concentrations, may in the long run increase the

112 Tacrolimus trough concentrations (mean/variability), as well as con

113 o groups that received proactive monitoring (trough concentrations measured at weeks 4 and 8 and then

114 Daily doses used and trough concentrations measured were compared in 12 LDLT

115 The median (interquartile range) trough concentrations (mg/L) for meropenem was 12.1 (7.8

116 Using CLSI and EUCAST methodologies, the trough concentration:MIC values that achieved suppressio

117 Although non-trough concentrations might have underestimated the freq

118 -dose-fits-all"), to mycophenolic acid (MPA) trough concentration monitoring, to dose optimization to

119 olimus clearance (daily tacrolimus dose [mg]/trough concentration [mug/L]) and biopsy-proven acute re

120 The alisertib steady-state trough concentration (n = 25) revealed the expected phar

121 Interestingly, the trough concentrations obtained from the bell-shaped curv

122 groups: personalised EID with a target drug trough concentration of 10 ug/mL (EID10), an exploratory

123 ice daily with dose adjustment to maintain a trough concentration of 100 to 125 ng/mL.

124 fied doses that achieve a target therapeutic trough concentration of 2-8 mg/L.

125 rs than 3435CC homozygotes at an average SRL trough concentration of 4 ng/mL without concomitant medi

126 are meter of body-surface area, to achieve a trough concentration of 5 to 15 ng per milliliter.

127 Interval extension to a drug trough concentration of 5 ug/mL is likely a safe target

128 +/- 57 mug/mL, which exceeded the effective trough concentration of 60 mug/mL observed in xenograft

129 o two groups based on a discharge tacrolimus trough concentration of 8 ng/mL.

130 Median estimated trough concentration of trastuzumab at the end of 3 week

131 cipients randomized to everolimus, targeting trough concentrations of 3-8 or 6-12 ng/mL plus reduced-

132 rvals of adalimumab were adjusted to achieve trough concentrations of 5 mug/mL.

133 5 mg/m(2) per day (titrated to achieve blood trough concentrations of 5-15 ng/mL) or placebo.

134 sted subject to tolerability to attain blood trough concentrations of 5-15 ng/mL.

135 With mean trough concentrations of 7 ng/ml and higher, grafts surv

136 /20 (100%) of those with peak, midpoint, and trough concentrations of antipseudomonal agents, respect

137 apy might not be a direct function of plasma trough concentrations of C1 inhibitor.

138 found a significant association between low trough concentrations of CAB and RPV and episodes of det

139 Trough concentrations of everolimus and octreotide were

140 l serum, breast milk, and infant serum daily trough concentrations of lithium averaged 0.76, 0.35, an

141 of clinically meaningful peak, midpoint, and trough concentrations of meropenem, imipenem, cefepime,

142 Overall exposure and trough concentrations of pembrolizumab s.c. 790 mg q6w w

143 The mean steady state peak and trough concentrations of rituximab were 461 mug/mL (SD 9

144 raction, namely increases in the whole blood trough concentrations of SRL ([SRL(WB)]) and CsA ([CsA(W

145 Lower trough concentrations of tacrolimus (6-10 ng/mL during t

146 We hypothesized that current trough concentrations of tacrolimus after liver transpla

147 pressers, exhibit higher clearance and lower trough concentrations of tacrolimus than homozygous none

148 concentration, AUC(0-12 hours), and predose trough concentrations of tipifarnib.

149 The trough concentrations of valspodar were > or = 1,000 ng/

150 verage reduction in ARV exposure of ~20% and trough concentrations of ~6% in obese (BMI >=30 kg/m2) c

151 Predose (trough) concentrations of HTT(Rx) in CSF showed dose dep

152 rted medication adherence scale and IS blood trough concentrations over 6 months, in four transplant

153 lected in the standard monitoring parameter, trough concentrations (P=0.80).

154 pregnancy make interpretation of whole blood trough concentrations particularly challenging.

155 cenarios were investigated by using peak and trough concentration, peak concentration solely, trough

156 Ganciclovir trough concentrations ranged from 0.31 to 3.16 ug/mL, an

157 reached during cycle 3 with mean maximum and trough concentrations ranging from 419 mug/mL (geometric

158 h dose adjustments to maintain predetermined trough concentration, regardless of disease activity) wi

159 Trough concentrations remained consistent throughout the

160 tles inoculated with the peak, midpoint, and trough concentrations, respectively (P </= 0.001).

161 24 (58%) of bottles with peak, midpoint, and trough concentrations, respectively (P = 0.221).

162 034) of those exposed to peak, midpoint, and trough concentrations, respectively.

163 ntinuation, conversion to reduced TAC target trough concentrations resulted in significantly improved

164 gh concentration, peak concentration solely, trough concentration solely, or covariate information (a

165 Mean trough concentration (+/- standard deviation) at 9 mg/kg

166 Everolimus trough concentrations targeted to 3-8 ng/mL, along with

167 reduced using an algorithm to reach a target trough concentration (TC) of 3-7 mug/mL in all patients

168 l studies) to determine how lower tacrolimus trough concentrations than currently recommended affect

169 ntration-dependent activity, and resulted in trough concentration that would minimize the risk of myo

170 e were no significant differences in neither trough concentrations the first week after transplantati

171 imed to assess the variability of antibiotic trough concentrations, the influence of effluent flow ra

172 nous fluconazole appear to increase oral CNI trough concentrations to a similar extent even after adj

173 ulation pharmacokinetic models by using only trough concentrations to estimate AUC24h has not been ev

174 ides non-inferior cycle 7 pertuzumab serum C(trough) concentrations to intravenous pertuzumab plus tr

175 ected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%).

176 Mean plasma trough concentration was 0.57 microg/mL (approximately 1

177 The median (Q1, Q3) dolutegravir trough concentration was 1751 ng/mL (1195, 2542) on day

178 dose to achieve 90% target engagement at the trough concentration was determined to be 40 mg administ

179 Despite the lower doses used, mean trough concentration was significantly greater in LDLT a

180 administration, the estimated protective TFV trough concentration was substantially higher in high-ri

181 GMR (90% CI) for the trough concentrations was 0.71 (.49-1.02), based on tota

182 or (rRMSE) for the AUC24h precision based on trough concentrations was similar to the rRMSE based on

183 wild-type virus, the efficacy of the PIs at trough concentrations was unaffected by a 4-fold increas

184 es were 4.4 and 4.5 mg/d and mean tacrolimus trough concentrations were 5.8 and 5.9 ng/mL before and

185 es were 4.6 and 4.6 mg/d and mean tacrolimus trough concentrations were 6.1 and 5.9 ng/mL before and

186 Adequate trough concentrations were achieved in all patients with

187 treatment, FTY720 effective doses and 24 hr trough concentrations were at least tenfold lower in com

188 ally in individuals with BMI >40 kg/m2 whose trough concentrations were below the clinical target thr

189 Infliximab trough concentrations were collected during the maintena

190 In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated w

191 ety and tolerability, and plasma CAB and RPV trough concentrations were evaluated by baseline BMI (<3

192 NVP trough concentrations were highly variable and below the

193 RPV trough concentrations were measured in 384 rectal sample

194 High serum linezolid trough concentrations were measured in approximately one

195 Trough concentrations were measured on 670 samples (medi

196 Steady-state trough concentrations were reached by day 15 and did not

197 Median dolutegravir trough concentrations were significantly lower in the 3H

198 Tacrolimus doses and trough concentrations were similar between treatment gro

199 rican Americans (n=684), but mean tacrolimus trough concentrations were similar.

200 NVP trough concentrations were tested at 1 and 2 weeks.

201 Individual dolutegravir C(trough) concentrations were higher than the 90% effectiv

202 after the occurrence of VF, and drug plasma (trough) concentrations were measured after VF was establ

203 ount (other covariates, including tacrolimus trough concentrations, were nonsignificant).

204 t month 1 or in area under the curve0-4h and trough concentration when measured at months 3 and 6.

205 paring proactive TDM (routine assessments of trough concentration with dose adjustments to maintain p

206 and positive association of the fluconazole trough concentration with the fluconazole dose (P <.001)

207 iolytic effect in subjects with SAD although trough concentrations with 25 mg once daily appeared to

208 Dolutegravir trough concentrations with 50 mg twice-daily dosing duri

209 119 mg/L, which is higher than steady-state trough concentrations with a conventional weekly or ever

210 med to evaluate the association of linezolid trough concentrations with severe toxicity.

211 Overall geometric mean ratio of trough concentrations with versus without rifapentine-is

212 The median proportion of tacrolimus trough concentrations within the target range was compar